Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug

Aliment Pharmacol Ther. 2024 Jan;59(1):140-141. doi: 10.1111/apt.17770.

Authors

Danny Con^{1

2}, Ashish Srinivasan^{1

2}

Affiliations

¹ Department of Gastroenterology, Austin Health, Melbourne, Australia.
² Department of Medicine, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Melbourne, Australia.

PMID: 38085945
DOI: 10.1111/apt.17770

No abstract available

Publication types

Letter

MeSH terms

Adalimumab
Antibodies, Monoclonal, Humanized / therapeutic use
Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / drug therapy
Humans
Infliximab / therapeutic use

Substances

Infliximab
vedolizumab
Antibodies, Monoclonal, Humanized
Adalimumab